About James Markmann, MD, PhD

James F. Markmann MD, PhD is the Chief of the Division of Transplant Surgery and Director of Clinical Operations at the Transplant Center at Massachusetts General Hospital, and the Claude Welch Professor of Surgery at Harvard Medical School. He specializes in liver, kidney, pancreas and islet transplantation as well as hemodialysis access surgery. He is active in numerous societies, editorial boards and organizations and is currently secretary of the International Pancreas and Islet Transplant Association and Councilor of the American Society of Transplant Surgeons. He has published more than 300 scientific papers over the last 30 years, most in the area of immune tolerance and pancreas and islet transplantation and has held continuous NIH R01 funding for >15 years. His current research interests include: 1) understanding the mechanism of action and therapeutic potential of regulatory B cells, 2) exploring the potential of ex vivo liver perfusion to improve marginal organ function, and 3) clinical trials in transplantation tolerance and pancreatic islet transplantation.

Clinical Interests:

Treats:

Locations

Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114-2696
617-643-4533
Fax: 617-643-4579

Dialysis Vascular Access
165 Cambridge Street
Suite 301
Boston, MA 02114-2751
617-643-0765
Fax: 617-643-7409

Transplant Surgical Center
55 Fruit Street
Boston, MA 02114-2696
617-643-4533
617-726-6631
Fax: 617-643-4579

Medical Education

  • MD, PhD, University of Pennsylvania School of Medicine
  • Residency, Hospital of the University of Pennsylvania
  • Fellowship, UCLA Medical Center

American Board Certifications

  • Surgery, American Board of Surgery

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Research

Dr. Markmann's research interests include 1) developing ways to perform transplants without immunosuppression, 2) new approaches to alleviate the organ shortage, and 3) utilizing pancreatic islets to treat patients with Type I diabetes. Dr. Markmann has published over 250 scientific papers and his research work is funded by the NIH and JDRF.